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Calmodulin (CaM) association with the cardiac muscle ryanodine receptor (RyR2) regulates excita-
tion–contraction coupling. Defective CaM–RyR2 interaction is associated with heart failure. A novel
CaM mutation (CaMF90L) was recently identiﬁed in a family with idiopathic ventricular ﬁbrillation
(IVF) and early onset sudden cardiac death. We report the ﬁrst biochemical characterization of
CaMF90L. F90L confers a deleterious effect on protein stability. Ca2+-binding studies reveal reduced
Ca2+-binding afﬁnity and a loss of co-operativity. Moreover, CaMF90L displays reduced RyR2 interac-
tion and defective modulation of [3H]ryanodine binding. Hence, dysregulation of RyR2-mediated
Ca2+ release via aberrant CaMF90L–RyR2 interaction is a potential mechanism that underlies familial
IVF.
Structured summary of protein interactions:
RyR2 physically interacts with CaM by pull down (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Calmodulin (CaM) is a small cytoplasmic Ca2+-binding protein
that regulates numerous cellular functions. CaM contains four
highly conserved Ca2+-binding EF hand motifs that each binds
one Ca2+ ion. The four EF hand motifs exist in two pairs and are
connected by a ﬂexible linker [1]. In cardiac muscle, CaM modu-
lates directly or indirectly the activity of proteins that play a key
role in excitation–contraction coupling (ECC), and in particular,
those responsible for the release and subsequent sequestration of
cytosolic Ca2+ into the sarcoplasmic reticulum (SR). The main bind-
ing partner of CaM in cardiac cells is the RyR2, which regulates Ca2+release from the SR. CaM binds to RyR2 stoichiometrically (1 CaM
per subunit of the homotetrameric RyR2). The CaM binding domain
is believed to reside within residues 3583–3603 of the RyR2 [2–4].
It has been shown that CaM inhibits RyR2 channel open probability
at nM to mM Ca2+ concentrations [4]. Defective CaM–RyR2 binding
resulting in impaired CaM inhibition of RyR2 function has been
widely implicated in cardiac pathology. Decreased or abolished
CaM binding to RyR2 has been associated with defective SR
Ca2+ release and altered gene expression, leading to cardiac hyper-
trophy and early death in animal models [5]. Moreover, defective
CaM binding to RyR2 has been linked with catecholaminergic
polymorphic ventricular tachycardia (CPVT)-associated RyR2 dys-
function [6].
Recent genetic studies have identiﬁed ﬁve missense CaM muta-
tions associated with severe ventricular arrhythmia and sudden
cardiac death susceptibility [7,8]. Two CaM mutations were associ-
ated with stress-induced polymorphic ventricular tachycardia
reminiscent of CPVT (CPVT-CaMs) [7], whereas the other three
mutations led to recurrent cardiac arrest in infancy associated
with severe QT prolongation reminiscent of a long QT syndrome
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revealed that the CPVT-CaM mutations caused higher RyR2 single
channel open probability and showed enhanced binding afﬁnity
to RyR2. In contrast, LQTS-CaMs did not promote Ca2+ waves and
exhibited either normal regulation of RyR2 single channels or
lower RyR2 binding afﬁnity [9].
Another recent study has reported a CaM mutation (Phe90Leu;
CaMF90L) as the causative genetic defect in a family of Moroccan
descent presenting with idiopathic ventricular ﬁbrillation (IVF)
in childhood and adolescence [10]. IVF is a rare cardiac rhythm
disorder, characterized by VF in the absence of electrocardio-
graphic or structural heart abnormalities. IVF represents a major
diagnostic challenge as it is difﬁcult to track genetically because
the affected status of an individual only becomes apparent
following an arrhythmic event [10]. CaMF90L has not been charac-
terized and the mechanism describing how it causes IVF is
unknown.
Here we report that the CaMF90L mutation fundamentally alters
the protein’s biophysical and biochemical properties. Thermal cir-
cular dichroism (CD) studies reveal that in the presence of Ca2+,
CaMF90L displays considerably lower stability than CaMWT, indicat-
ing a loss in co-operativity of unfolding. This result is consistent
with chemical denaturation experiments showing that the CaMF90L
mutation causes a destabilization of the C-domain, resulting in a
signiﬁcantly reduced C-domain Ca2+ afﬁnity and a total loss of
co-operativity between the Ca2+-binding sites in this domain.
Native RyR2 co-immunoprecipitation with recombinant CaMWT
and CaMF90L revealed that the F90L mutation impairs CaM–RyR2
interaction. This is compatible with [3H]ryanodine binding studies
which suggest that CaMF90L loses its ability to inhibit the RyR2
channel at a speciﬁc range of Ca2+ concentrations. These observa-
tions imply that CaMF90L may cause IVF due to a defective interac-
tion with RyR2 leading to dysregulated SR Ca2+ release.2. Material and methods
A detailed description of methods is provided in the Supple-
mentary Materials section.
3. Results and discussion
CaMWT and CaMF90L were cloned into the pHSIE plasmid vector
which expresses a fusion protein containing an N-terminal 6His-
tag, followed by a SUMO2-tag, the protease intein and an intein
cleavage site. This enables the auto-cleavage of the fusion tags dur-
ing the one-step puriﬁcation protocol detailed in Material and
Methods (see Supplementary Materials) [11]. Fig. 1A shows the
afﬁnity-puriﬁed recombinant CaM proteins analyzed by SDS–PAGE
and anti-CaM immunoblot analysis with the 17.4 kDa predicted
molecular mass for CaMWT and CaMF90L observed in both the gel
(left-hand panel) and immunoblot (right-hand panel).
CD spectra of both CaMWT and CaMF90L recorded at low temper-
ature are nearly identical and in very good agreement with previ-
ously published spectra [12] conﬁrming proper protein folding
(Fig. 1B). Ca2+ binding results in an increase in the CD amplitude
indicating an increase in the a-helical content and a decrease in
the ratio of De208nm/De221nm (Fig. 1B). In the absence of Ca2+, both
proteins show very similar thermal denaturation behavior with
melting temperatures (Tm) of 53.8 ± 0.2 and 58.0 ± 0.2 C, and van’t
Hoff enthalpies (DHvH) of 112 ± 1.8 and 126 ± 2.9 kJ/mol for the
CaMWT and CaMF90L, respectively (Fig. 1B). These values agree well
with those reported for CaMWT previously [13]. Addition of Ca2+
has a stabilizing effect resulting in an increased Tm, estimated at
105 ± 0.2 C and DHvH = 105 ± 1.6 kJ/mol for CaMWT. In contrast,
CaMF90L showed considerably lower thermostability withTm = 87.3 ± 1.5 C and DHvH = 33 ± 0.4 kJ/mol, indicating a loss
in the co-operativity of unfolding.
To further investigate the biophysical impact of the F90L muta-
tion we studied the chemically-induced unfolding of both CaMWT
and CaMF90L by monitoring their tyrosine ﬂuorescence emission
intensity (kex = 277) at 320 nm. Since the ﬂuorescence emissions
from the N-domain is practically zero at this excitation wavelength
[14], the collected data reﬂect only the thermodynamic stability of
the C-domain. Fig. 1C shows ﬂuorescence data for the
GuHCl-induced denaturation of both protein samples. Table 1
(Supplementary Material section) summarizes the results of a
two-state model nonlinear least-squares ﬁt to the experimental
data. These data indicate that the F90L mutation has a negative
effect on the protein stability as it destabilizes the C-domain by
almost 60% (DDG = 3.0 kJ/mol) at 25 C.
To understand the biochemical impact of the F90L mutation on
the Ca2+-binding properties of CaMWT, we performed in vitro Ca2+
binding studies by monitoring the intrinsic ﬂuorescence. VanScyoc
et al. [14,15] previously demonstrated that Ca2+-dependent
changes in Phe ﬂuorescence speciﬁcally indicate ion occupancy
within the N-domain, as Phe residues in the C-domain are non-
emissive. In a similar fashion, they proved that Tyr emission from
the C-domain does not interfere with Phe ﬂuorescence signals from
the N-domain, allowing selective insight to the Ca2+-binding prop-
erties of each of the four sites within CaM. Using 277 nm excita-
tion/320 nm emission to monitor Tyr ﬂuorescence, we
determined that both CaMWT and CaMF90L exhibited an increase
in ﬂuorescence intensity as a function of free Ca2+ concentration
(Fig. 2A,I). The situation is reverted when using 250 nm excita-
tion/280 nm emission for selective Phe ﬂuorescence. In this case,
the ﬂuorescence intensity decreases with increasing free Ca2+
concentration (Fig. 2A,II). Averaged binding data from three inde-
pendent titrations following nonlinear least-squares ﬁtting are
summarized in Table 2 (Supplementary Material section). For
CaMWT, C-domain binding sites have an afﬁnity for Ca2+ that is
3-fold higher than that of the N-domain binding sites (apparent
Kd of 2.9 ± 0.1 and 7.2 ± 0.2 lM, respectively, Table 2, Supplemen-
tary Material section). The free energy change accompanying
binding of two Ca2+ ions at the C-domain binding sites was found
to be 63.18 ± 0.42 kJ/mol with a co-operative free energy of
5.52 ± 0.92 kJ/mol, while the corresponding values for the N-
domain binding sites were 58.58 ± 0.42 and 5.94 ± 0.92 kJ/mol,
respectively. These calculations are in good agreement with earlier
studies under the same experimental conditions [8,13]. For
CaMF90L, the N-domain binding sites appear to have higher Ca2+
afﬁnity than their C-domain counterparts (13.1 ± 0.3 and
24.1 ± 1.5 lM respectively), as a result of the close proximity of
the Phe90 residue to the C-domain active sites. Examining the C-
domain Ca2+ binding energetics of CaMWT and the CaMF90L mutant,
it is evident that the main difference lies with the free energy
change associated with the capture of a second Ca2+ while the ﬁrst
site is already occupied (DGsite 2 = 63.18 ± 0.42 kJ/mol vs.
52.72 ± 0.42 kJ/mol for CaMWT vs. CaMF90L) and the co-operative
free energy of the two binding sites (DGcoop = 5.52 ± 0.92 kJ/mol
for CaMWT vs. 0.42 ± 0.21 kJ/mol for CaMF90L). Working under
the assumption of equivalency for the two Ca2+ binding sites, these
data taken together suggest an almost complete loss of co-oper-
ativity for CaMF90L at the C-domain. The F90L mutation most likely
disrupts the relative position of the two binding sites, thus interfer-
ing with the ability of the ﬁrst occupied site to induce conforma-
tional changes that facilitate binding to the second site. Co-
operative binding is very important for CaM, as it produces a nar-
row Ca2+ concentration range for the protein to switch from the
apo- to the holo- form, whereas having active protein over a broad
Ca2+ concentration range makes it less efﬁcient as a biological Ca2+
sensor. The combined effect of decreased domain stability and loss
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Fig. 1. (A) Expression and puriﬁcation of recombinant CaMWT and CaMF90L proteins. Afﬁnity-puriﬁed proteins (1 lg) were analyzed by 15% SDS–PAGE followed by either
Coomassie Brilliant Blue staining (left panel) or immunoblot analysis using an anti-CaM rabbit monoclonal antibody (1:7500 dilution); (right panel). (B) CD spectra of CaMWT
(black, blue) and the CaMF90L mutant (red, green) are shown in the absence (upper left panel) and presence (upper right panel) of Ca2+ recorded at low and high temperature,
as indicated. Thermal denaturation curves measured at 221 nm are shown in the lower panel. (C) Chemical denaturation proﬁles, induced by GuHCl under equilibrium
conditions at 25 C, of CaMWT ( ) and CaMF90L mutant ( ) in apo-buffer. Solid lines represent the nonlinear least-squares ﬁt of a two-state unfolding model to each set of
experimental data (upper panel). Scatter plot of residuals generated by the curve-ﬁtting procedure (lower panel).
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a profound impact on the biological functions of the CaMF90L
mutant.
RyR2 is the major binding partner for CaM along the Z-line in
cardiomyocytes, and aberrant CaM dissociation from RyR2 can
cause heart failure. In heart failure, RyR2 shows decreased interac-
tion with CaM but unaltered FKBP12.6 afﬁnity [4]. To compare the
relative RyR2-binding afﬁnities of recombinant CaMWT and CaMF90L
we used a co-immunoprecipitation assay as detailed inMaterial andMethods (see Supplementary Material section). Native RyR2 from
pig cardiac SR was immunoprecipitated with an RyR2-isoform-spe-
ciﬁc antibody (Ab1093) in the presence of either recombinant CaMWT
or CaMF90L. Association of CaMWT and CaMF90L with RyR2 was ana-
lyzed by SDS–PAGE and immunoblot detection using an anti-CaM
antibody. Densitometric analysis showed that CaMF90L had a 50%
reduced RyR2-binding compared to CaMWT in the absence of Ca2+
and 30% reduced RyR2-binding afﬁnity in the presence of either
10 or 100 lM free [Ca2+] (Fig. 2B). The level of endogenous CaM
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Fig. 2. (A) Ca2+ titration proﬁles of CaMWT ( ) and CaMF90L mutant ( ) in apo-buffer, monitored at two pairs of wavelength: 277 nm excitation/320 nm emission (I) and
250 nm excitation/280 nm emission (II). Blue and red dashed lines represent the nonlinear least-squares ﬁt of a two-site, model-independent Adair function for the CaMwild-
type and F90L mutant data, respectively. (B) Co-immunoprecipitation assays showing the association of CaMWT and CaMF90L mutant with cardiac RyR2. Native RyR2 was
immunoprecipitated with Ab1093 from CHAPS-solubilised cardiac SR in the presence of 1 lM of exogenous CaMWT or CaMF90L at different Ca2+ concentrations (0, 10 &
100 lM). The presence of RyR2-coprecipitated CaMWT and CaMF90L mutant was analyzed by 18% SDS–PAGE followed by immunoblot analysis using an anti-CaM rabbit
monoclonal antibody (1:7500 dilution); (upper panel). Densitometry analysis and normalization followed three independent experiments using three different pig cardiac SR
preparations (lower panel), ⁄P < 0.05 (GraphPad, Prism 5). (C) Effect of CaMWT and CaMF90L on [3H]ryanodine binding to cardiac SR vesicles. The basic binding buffer contained
50 mM HEPES, 25 mM Tris, 500 mM KCl, pH 7.4 with either 1 mM EGTA (less than 0.01 lM Ca2+) or a series of free Ca2+ concentrations. At least 2 different cardiac SR vesicle
preparations were used. Signiﬁcant effects (asterisks) were calculated by comparison of each point using an unpaired Student’s t-test. n = 4 ± S.E.M., ⁄P < 0.05, (GraphPad,
Prism 5). (D) (a) Solid space-ﬁlling surface of residue F90 (orange) of CaMF90L is shown completely engulfed inside the semi-transparent surface of residues with atoms that
are within 4 Å distance of F90 (blue), shown as sticks. Figure is based on 1YR5. The rest of the protein is shown as cartoon. The Ca2+ atoms of the EF hand motifs are shown as
green spheres. (b) This is the same as for (a) but after removing the surfaces. The side chain of F90 is shown in orange ball-and-stick, and the modelled side-chain of the Leu
mutation is in green. (c, d) These panels correspond to (a, b) respectively, but with the view rotated 180 about the vertical axis (i.e. back view).
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immunoblotting with the anti-CaM antibody. There was no native
CaM detected using this approach, whereas blots containing either
10 or 25 ng of recombinant CaM was readily detected by this
antibody (Supplementary Fig. 1).The binding of [3H]ryanodine to RyR2 depends on the functional
state of the channel, and thus represents a useful tool to analyze
the action of modulators of Ca2+ release channel function such as
CaM. The effect of CaMWT and CaMF90L on [3H]ryanodine binding
to RyR2 was studied at a range of Ca2+ concentrations from
2902 M. Nomikos et al. / FEBS Letters 588 (2014) 2898–290210 nM to 100 lM. As shown in Fig. 2C, CaMF90L showed a 65–85%
reduced inhibition of ryanodine binding to RyR2 compared to
CaMWT. This result is consistent with the co-immunoprecipitation
experiments that revealed impaired RyR2–CaMF90L association
(Fig. 2B) and suggest that defective CaM–RyR2 interaction leading
to dysregulated SR Ca2+ release in cardiomyocytes might explain
the molecular mechanism for how the F90L mutation leads to
IVF and sudden cardiac death (SCD).
The F90L mutation is located within the inter-EF hand linker
between the 2nd and 3rd EF hand domains. Fig. 2D shows the
F90 surface, which ﬁts inside an envelope formed by the neigh-
bouring residues with at least one atom within 4 Å from F90. The
‘front’ and ‘back’ views provide a better perspective of the relative
orientation. Also shown are the two views without the surfaces,
emphasising the wrap-around disposition of the neighbouring res-
idues. The Leu mutation, also shown in Fig. 2D-b,d highlights the 3
atom sites from the Phe side chain that cannot be ﬁlled by Leu. This
vacancy may presumably affect the protein folding stability, as was
shown by the decreased stability both by thermal and chemical
denaturation (Fig. 1B and C). However, from the high stability
shown by the CD measurements, complete protein misfolding is
not apparent. Instead the decreased protein stability is consistent
with local misfolding, as indicated by the hydrophobic packing of
the F90 residue. Moreover, it could allow for a smaller gap between
the two Ca2+ binding sites in the neighbouring EF motifs. A closer
distance between the two motifs presents an altered topology for
binding, and effects a disparate energy requirement for conforma-
tional change from the unbound conformation. These hypotheses
for the F90L mutation in CaM would have to be underwritten with
a high-resolution 3D crystal structure for CaMF90L in due course.
There are 3 human CaM genes and patients with the F90L muta-
tion are heterozygous, raising the issue of how the reduced afﬁnity
of a mutant CaM (1 of 6 copies) could affect RyR2 function. It is
possible that a CaM mutant with lower RyR afﬁnity may act in a
dominant-negative fashion, as there are believed to be four CaM
binding sites per RyR tetramer. Also, because the RyRs can form
into 2Dmembrane clusters of interlinked oligomers, a single defec-
tive RyR (with only one mutant CaM bound) potentially could
affect the function of a large number of RyRs within the 2D array.
In addition, the relative expression of each of the CaM genes is not
equal and this differential gene expression may play an important
role. These important points require further study.
This is the ﬁrst structure–function analysis providing an insight
into the biochemical mechanism for how the F90L mutation might
lead to IVF and SCD. Our results suggest that the F90L mutation in
CaM results in altered Ca2+ binding which leads to reduced ability
to interact with the RyR2 thus consequently producing dysregu-
lated Ca2+ release. However, further studies of the effect of this
CaM F90L mutant on single channel recordings of the human
RyR2 functionally reconstituted into planar lipid bilayers, on car-
diomyocyte intracellular Ca2+ release assays using ﬂuorimetric
Ca2+ imaging and the distinct possibility that the mutant CaM
may also affect other CaM-regulated cardiac ion channels, Ca2+
ATPases and cytoplasmic protein targets such as, calcineurin &
CaM-dependent protein kinases (CaMK) [16], all require further
investigation.Conﬂict of interest
None declared.Sources of funding
VV and MT are research scholars supported by NCSR Demokri-
tos. HH is a research placement scholar supported by the Wales
Heart Research Institute.
Acknowledgments
We are grateful to Zenon Grabarek (Boston Biomedical Research
Institute, USA) for providing the human CaM plasmid, and to Xuex-
un Fang (Jilin University, China) for providing the pHSIE vector.
Appendix A. Supplementary data
Supplementary data associated with this article can be found, in
the online version, at http://dx.doi.org/10.1016/j.febslet.2014.
07.007.
References
[1] Tadross, M.R., Dick, I.E. and Yue, D.T. (2008) Mechanism of local and global
Ca2+ sensing by calmodulin in complex with a Ca2+ channel. Cell 133, 1228–
1240.
[2] Yamaguchi, N., Xu, L., Pasek, D.A., Evans, K.E. and Meissner, G. (2003)
Molecular basis of calmodulin binding to cardiac muscle Ca(2+) release
channel (ryanodine receptor). J. Biol. Chem. 278, 23480–23486.
[3] Balshaw, D.M., Xu, L., Yamaguchi, N., Pasek, D.A. and Meissner, G. (2001)
Calmodulin binding and inhibition of cardiac muscle calcium release channel
(ryanodine receptor). J. Biol. Chem. 276, 20144–20153.
[4] Yang, Y., Guo, T., Oda, T., Chakraborty, A., Chen, L., Uchinoumi, H., et al. (2014)
Cardiac myocyte Z-line calmodulin is mainly RyR2-bound, and reduction is
arrhythmogenic and occurs in heart failure. Circ. Res. 114, 295–306.
[5] Yamaguchi, N., Takahashi, N., Xu, L., Smithies, O. and Meissner, G. (2007) Early
cardiac hypertrophy in mice with impaired calmodulin regulation of cardiac
muscle Ca release channel. J. Clin. Invest. 117, 1344–1353.
[6] Xu, X., Yano, M., Uchinoumi, H., Hino, A., Suetomi, T., Ono, M., et al. (2010)
Defective calmodulin binding to the cardiac ryanodine receptor plays a key
role in CPVT-associated channel dysfunction. Biochem. Biophys. Res. Commun.
394, 660–666.
[7] Nyegaard, M., Overgaard, M.T., Sondergaard, M.T., Vranas, M., Behr, E.R.,
Hildebrandt, L.L., et al. (2012) Mutations in calmodulin cause ventricular
tachycardia and sudden cardiac death. Am. J. Hum. Genet. 91, 703–712.
[8] Crotti, L., Johnson, C.N., Graf, E., De Ferrari, G.M., Cuneo, B.F., Ovadia, M., et al.
(2013) Calmodulin mutations associated with recurrent cardiac arrest in
infants. Circulation 127, 1009–1017.
[9] Hwang, H.S., Nitu, F.R., Yang, Y., Walweel, K., Pereira, L., Johnson, C.N., et al.
(2014) Divergent regulation of RyR2 calcium release channels by
arrhythmogenic human calmodulin missense mutants. Circ. Res. 114, 1114–
1124.
[10] Marsman, R.F., Barc, J., Beekman, L., Alders, M., Dooijes, D., van den Wijngaard,
A., et al. (2014) A mutation in CALM1 encoding calmodulin in familial
idiopathic ventricular ﬁbrillation in childhood and adolescence. J. Am. Coll.
Cardiol. 63, 259–266.
[11] Wang, Z., Li, N., Wang, Y., Wu, Y., Mu, T., Zheng, Y., et al. (2012) Ubiquitin-
intein and SUMO2-intein fusion systems for enhanced protein production and
puriﬁcation. Protein Expr. Purif. 82, 174–178.
[12] Hennessey Jr., J.P., Manavalan, P., Johnson Jr., W.C., Malencik, D.A., Anderson,
S.R., Schimerlik, M.I., et al. (1987) Conformational transitions of calmodulin as
studied by vacuum-uv CD. Biopolymers 26, 561–571.
[13] Sorensen, B.R. and Shea, M.A. (1998) Interactions between domains of apo
calmodulin alter calcium binding and stability. Biochemistry 37, 4244–4253.
[14] VanScyoc, W.S., Sorensen, B.R., Rusinova, E., Laws, W.R., Ross, J.B. and Shea,
M.A. (2002) Calcium binding to calmodulin mutants monitored by domain-
speciﬁc intrinsic phenylalanine and tyrosine ﬂuorescence. Biophys. J. 83,
2767–2780.
[15] VanScyoc, W.S. and Shea, M.A. (2001) Phenylalanine ﬂuorescence studies of
calcium binding to N-domain fragments of Paramecium calmodulin mutants
show increased calcium afﬁnity correlates with increased disorder. Protein
Sci. 10, 1758–1768.
[16] Di Pasquale, E., Lodola, F., Miragoli, M., Denegri, M., Avelino-Cruz, J.E.,
Buonocore, M., et al. (2013) CaMKII inhibition rectiﬁes arrhythmic
phenotype in a patient-speciﬁc model of catecholaminergic polymorphic
ventricular tachycardia. Cell Death Dis. 4, e843.
